Re: Waldemar Marszałek otyłość niedoczynność tarczycy stluszczenie wątroby cukrzyca

Official Journal of the European Platform for Photodynamic Medicine
Affiliated with the International Photodynamic Association
Also affiliated with the British Medical Laser Association and the
Polish Society for Photodynamic Medicine
INDEXED in MEDLINE/PubMed, SciSearch/Science Citation Index …
View full aims & scope
Elsevier's Oncology Journal Network
From January 1, 2024, Photodiagnosis and Photodynamic Therapy will
become a full gold open access journal freely available for everyone to
access and read. All articles submitted after August 31, 2023, are
subject to an article publishing charge (APC) after peer review and
acceptance. Learn more about hybrid journals moving to open access.
$2450
Article publishing charge
for open access
===
Thérapie photodynamique (TPD) pour le cancer de la peau
La thérapie photodynamique (TPD) tue les cellules cancéreuses en
utilisant une combinaison d'un médicament photosensible et d'une lumière
très vive.
Le médecin applique une crème contenant le produit chimique
photosensible sur le cancer de la peau et la zone environnante. Vous
pouvez également recevoir le produit chimique sous forme de comprimé ou
d'injection. Votre médecin éclaire ensuite la zone à traiter avec une
lumière spéciale qui détruit les cellules cancéreuses.
Qu'est-ce que la thérapie photodynamique (TPD) ?
La thérapie photodynamique (TPD) est également appelée :
    thérapie par photoradiation
    photothérapie
    photochimiothérapie
La TPD associe un médicament qui rend les cellules sensibles à la
lumière à une exposition à un type particulier de lumière. Ce médicament
est appelé photosensibilisateur ou agent photosensibilisant.
====
INTERNATIONAL PHOTODYNAMIC ASSOCIATION
The International Photodynamic Association (IPA) was founded in 1986 to
support and endorse the scientific advancement and clinical development
of photomedicine, in particular in the areas of photodynamic
disinfection, photodynamic therapy (PDT), photoimmunotherapy (PIT), and
photodiagnosis (PD). With members and associates from over 30 countries,
the IPA represents a truly global community consisting of prominent
international scientists, clinical and translational researchers,
healthcare professionals and students across academic, hospital,
government and private sector organizations. The IPA promotes the study
of diagnosis and treatment using light-activated photosensitizers and
disseminates scientific information to its members, the research
community, and to the community at large. The IPA organizes a Biennial
World Congress, providing members and non-members a unique opportunity
to share and learn more about global developments and research in
photodynamic therapy, photoimmunotherapy and photodiagnosis.
----
PDT IN CHINA
Photodynamic therapy (PDT) originated in Germany. In 1900, Oscar Raab, a
medical student at the University of Munich in Germany, accidentally
discovered that paramecium grew well in a dark environment in a culture
medium containing acridine and some similar dye solutions, but died when
exposed to light; Further research has found that this phenomenon is not
only related to the concentration of acridine dyes, but also to the
intensity of light in the experiment. This is the first experimental
study on photodynamic therapy, confirming that light combined with
chemicals can induce cell death, opening the prelude to photodynamic
research.
===
The 34th Annual Meeting of the Japan Photodynamic Association (JPA)
July 13, 2024
Previous
19th International Photodynamic Association World Congress, China 2025
Next
Contribute to an article for a special issue of Photodiagnosis and
Photodynamic Therapy with the title -  Photosensitizing dyes: state of
the art
===
November 27-29, 2023
4th International Conference on Photopharmacology
Join us for the latest in design, synthesis and application of drugs and
molecular probes controlled by light!
Started in Groningen in 2017, then hosted in Barcelona in 2018, in New
York (by Zoom) in 2021, we are proud to host the 4th installment of
Photopharmacology. This event is co-organized by Department of
Pharmacology & Pharmacy, The State Key Laboratory of Pharmaceutical
Biotechnology, and Dr Li Dak-Sum Research Centre, The University of Hong
Kong. The scientific program for Photopharmacology IV includes invited
and contributed lectures, as well as a vibrant poster session.
Dr Weiping Wang
The University of Hong Kong
Meeting Themes
Photopharmacology aims at using photosensitive compounds combined with
light irradiation to spatiotemporally control their structures and
functions. This property allows for the use of light as an external
control for therapeutic applications and research tools.
Photopharmacology is a multidisciplinary field that integrates
chemistry, biology, and pharmacology, which has been emerging rapidly in
the recent years. However, more problems still need to be solved for the
clinical translation of light-responsive materials. Bearing this in
mind, Photopharmacology IV seeks to bring together world experts in
photopharmacology to present, discuss, and collaborate between their own
areas of expertise. One topic of interest at the conference will be the
prospective clinical translation attempts of the light-responsive
compounds or materials, which are designed for the diagnosis and
treatment of cancer as well as skin and eye diseases, etc. Another topic
of interest is the relationship between photopharmacology and
photoresponsive drug delivery, which are based on similar photochemistry
techniques and application objectives. The design of novel
photosensitive molecules with long-wavelength excitation and high
responsiveness for deep-seated diseases will be discussed in terms of
photochemistry and light delivery. During the conference, emerging
photoswitches and photocaging groups that meet these challenges will be
introduced. In addition, new strategies on optogenetics, photodynamic
therapy and photothermal therapy will be introduced and discussed.